阿托伐他汀联合曲美他嗪对冠心病患者血浆纤维蛋白及心功能的影响

Effect of atorvastatin combined with trimetazidine on plasma fibrinogen and cardiac function in patients with coronary heart disease

目的探讨阿托伐他汀联合曲美他嗪对冠心病患者血浆纤维蛋白（Fib）及心功能的影响。方法选择在医院治疗的108例冠心病患者作为研究对象，根据入院就诊编号进行分组，每组54例。对照组口服曲美他嗪治疗，观察组采用阿托伐他汀联合曲美他嗪治疗，比较两组治疗效果、心功能[左心室后壁厚度（LVPWd）、左心室射血分数（LVEF）、左心室舒张末期内径（LVEDD）]以及生化指标[高敏C反应蛋白（hs-CRP）、白细胞介素-6（IL-6）、纤维蛋白原（Fib）]变化情况。结果经不同药物治疗后，观察组治疗效果明显优于对照组，差异有统计学意义（P〈0.05）；治疗前两组心功能指标相比，差异未见统计学意义（P〉0.05）；治疗后与对照组相比，观察组LVPWd、LVEDD水平均较低，而LVEF水平较高，差异有统计学意义（P〈0.05）；治疗前两组hs-CRP、IL-6、Fib等生化指标相比，差异未见统计学意义（P〉0.05）；治疗后两组hs-CRP、IL-6、Fib等指标均明显下降，且观察组明显低于对照组，差异有统计学意义（P〈0.05）。 结论冠心病患者采用阿托伐他汀联合曲美他嗪治疗能明显提高治疗效果，降低hs-CRP、IL-6、Fib等指标水平，增强心脏射血能力，从而改善患者心功能，值得临床广泛应用。

Objective To investigate the effect of atorvastatin combined with trimetazidine on plasma fibrinogen （Fib） and cardiac function in coronary heart disease （CHD）.MethodsA total of 108 CHD patients treated in hospital were selected, and they were divided into control group and observation group by registration order, with 54 cases in each group. The patients in the control group were treated with trimetazidine, and the patients in the observation group were treated with atorvastatin combined with trimetazidine. The curative effects, cardiac function [left ventricular posterior wall depth （LVPWd）, left ventricular ejection fraction （LVEF）, left ventricular end-diastolic dimension （LVEDD）], biochemical indexes [high sensitive C-reactive protein （hs-CRP）, interleukin-6 （IL-6）, Fib] changes of two groups were compared.ResultsAfter treatment with different drugs, the curative effect of observation group was significantly better than that of control group （P〈0.05）. Before treatment, there was no significant difference in the indexes of cardiac function between the two groups （P〉0.05）. After treatment, compared with control group, the LVPWd, LVEDD levels of observation group were lower, but LVEF level was higher （P〈0.05）. Before treatment, there was no significant difference in hs-CRP, IL-6, Fib between the two groups （P〉0.05）. After treatment, the levels of hs-CRP, IL-6, Fib of the two groups all significantly decreased, and those of the observation group were significantly lower than those of the control group （P〈0.05）.ConclusionsAtorvastatin combined with trimetazidine can significantly increase the curative effects on CHD patients, decrease the hs-CRP, IL-6, Fib levels, strengthen cardiac ejection ability, thus improving the cardiac function. It is worthy of wide clinical application.